Summit Therapeutics (NASDAQ:SMMT) Research Coverage Started at Cantor Fitzgerald
Cantor Fitzgerald began coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a research report sent to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock. A number of other brokerages have also commented on SMMT. HC Wainwright reissued a “buy” rating and set a $44.00 price […]
Cantor Fitzgerald began coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a research report sent to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock. A number of other brokerages have also commented on SMMT. HC Wainwright reissued a “buy” rating and set a $44.00 price […]
